Oct 8, 2021
Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild to moderate COVID-19 on 9 November 2020, 94 days after the monoclonal antibody discovery workflow began for the molecule. This achievement, says Eli Lilly, represents the shortest timeline from discovery to public usage for a monoclonal antibody to date. In February 2021, bamlanivimab administered with etesevimab received emergency use authorisation for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19.
Jones and Bedinger talk us through the Bamlanivimab story – and how one technology enabled this therapeutic to reach clinic in eight months during the pandemic.
Tune in to find out how Eli Lilly strategised and built multiple collaborations enabling this Covid-19 therapeutic to reach patients in just over eight months, plus details of Carterra’s involvement in the process.